Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 576 - 600 of 15440 in total

Fluconazole

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole...
Approved
Investigational
Matched Description: … This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. ... Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and …
Matched Categories: … Imidazole and Triazole Derivatives ... Triazole and tetrazole derivatives ... azithromycin, fluconazole and secnidazole ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Didanosine

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral...
Approved
Matched Description: … modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... Nucleic Acids, Nucleotides, and Nucleosides ... Nucleoside and Nucleotide Reverse Transcriptase Inhibitors …

Plazomicin

Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from DB12604. The structure of plazomicin was established via appending hydroxylaminobutyric acid to DB12604 at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main...
Approved
Investigational
Matched Description: … ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations [A33942 ... The structure of plazomicin was established via appending hydroxylaminobutyric acid to [DB12604] at position ... 1 and 2-hydroxyethyl group at position 6' [A33942]. …

Larotrectinib

Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … plays an important role in tumor cell growth and survival. ... receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and ... Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Flupentixol

Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid. Flupentixol is an antagonist of...
Approved
Investigational
Withdrawn
Matched Description: … injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid ... [A229083] Flupentixol is an antagonist of both D1 and D2 dopamine receptors. ... It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. …

Memantine

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's...
Approved
Investigational
Matched Description: … blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and ... doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and …
Matched Mixtures name: … Memantine and Donepezil Hydrochlorides Extended-release ... Memantine and Donepezil Hydrochlorides Extended-release ... Memantine and Donepezil Hydrochlorides Extended-release …
Matched Categories: … Excitatory Amino Acid Antagonists ... donepezil and memantine ... donepezil, memantine and Ginkgo folium …

Ferric maltol

Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency....
Approved
Matched Description: … bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and …
Matched Categories: … Blood and Blood Forming Organs …

Prednisone

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone was granted FDA approval on 21 February 1955.
Approved
Vet approved
Matched Description: … [A187463] It is biologically inert and converted to [prednisolone] in the liver. …
Matched Categories: … Alimentary Tract and Metabolism ... Prednisolone and Prodrugs ... Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Methsuximide

Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Approved

Levomilnacipran

Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Matched Categories: … Milnacipran and enantiomer ... Serotonin and Noradrenaline Reuptake Inhibitors …

Boldo leaf extract

Boldo leaf extract allergenic extract is used in allergenic testing.
Approved
Experimental

Laropiprant

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.
Approved
Investigational
Withdrawn
Matched Iupac: … 3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid …

Lemborexant

Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Description: … receptors, lemborexant and other orexin antagonists (e.g. ... receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and ... potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and …
Matched Categories: … Hypnotics and Sedatives ... Sleep Initiation and Maintenance Disorders …

Lenograstim

Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Lomifylline

Approved

Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Fidaxomicin

Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is...
Approved
Matched Description: … bactericidal activity is time-dependent, and not concentration-dependent. ... the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and ... [A190492] The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the …
Matched Categories: … Alimentary Tract and Metabolism …

Sulconazole

Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis infections.[L44592,L44597] Sulconazole appears to be effective...
Approved
Matched Description: … Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and ... [L44592,L44597] Sulconazole appears to be effective and well-tolerated in the treatment of superficial ... inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and …
Matched Categories: … Imidazole and Triazole Derivatives …

Reviparin

Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. It was developed by Abbott laboratories and in 2009, reviparin presented an orphan...
Approved
Investigational
Matched Description: … [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. ... [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …

Samarium (153Sm) lexidronam

Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium...
Approved
Investigational
Matched Description: … The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide …

Bromocriptine

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Description: … Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as ... It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia ... Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of …
Matched Categories: … Ergot Alkaloids and Derivatives ... Genito Urinary System and Sex Hormones ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Pascopyrum smithii pollen

Pascopyrum smithii pollen is the pollen of the Pascopyrum smithii plant. Pascopyrum smithii pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … Mixture of Twenty-Two Standardized and Non-Standardized Grasses …

Polidocanol

Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. It is marketed under the brand names Asclera and Varithena. The formula for Polidocanol has the structural...
Approved
Matched Description: … It is marketed under the brand names Asclera and Varithena. ... a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and ... has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and …

Aclidinium

Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Approved
Matched Categories: … formoterol and aclidinium bromide …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 576 - 600 of 15440 in total